Oxygen-independent free radical generation mediated by core-shell magnetic nanocomposites synergizes with immune checkpoint blockade for effective primary and metastatic tumor treatment
Source abstract
Abstract
Abstract Advanced or metastatic tumor treatment is a long-lasting problem that leads to high mortality. Photodynamic therapy (PDT) has emerged as a promising clinical therapeutic strategy with the ability of destroying local tumors and initiating systemic anti-tumor immune responses for metastasis inhibition. However, the efficacy is typically limited by tumor hypoxia, aggregation caused self-quenching of classic photosensitizers (PSs), and intrinsic or adaptive immune resistance that mediated by cellular and molecular immunosuppressive components. Here, we designed an oxygen-independent photosensitizer by core-shell magnetic nanocomposites (MNCs), with functionalized iron oxide nanoclusters as the core and coordination polymerization of Zinc Tetra (N-methyl-4-pyridyl) porphyrin (ZnTMPyP) as the shell. MNCs PDT induced persistent free radical generation via facilitating an effective electron-hole separation, polarized macrophages to pro-inflammatory M1 phenotype, and activated systemic antitumor immunity. Nevertheless, adaptive immune resistance occurred simultaneously, characterized by highly increased PD-L1 expression on tumor cells, dendritic cells (DCs) and macrophages. As a result, combined use of MNCs PDT with checkpoint blockade effectively suppressed well-established primary tumors as well as tumor metastasis via a ‘trident’ modality, including persistent free radical generation in both normoxic and hypoxic conditions for direct tumor destruction, enhanced frequency of tumor infiltrating-lymphocytes (TILs) and modified tumor immunosuppressive microenvironment with reduced immunosuppressive cells and PD-L1 blockade. We also explore the underlying mechanisms of metastasis inhibition according to the transcriptome expression profiling of lung tissues, which revealed that the ‘trident’ modality altered numerous genes mainly related to immuno-activation and cancer associated signaling pathways. We expect the expanded use of this platform for various types of cancer malignancy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Schroeder · Nat. Rev. Cancer · 2012 · 12 · 3910.1038/nrc3180 ↗
2. Fesnak · Nat. Rev. Cancer · 2016 · 16 · 56610.1038/nrc.2016.97 ↗
3. Yang · J. Clin. Invest. · 2015 · 125 · 333510.1172/JCI83871 ↗
4. Chen · Chem. Soc. Rev. · 2019 · 48 · 550610.1039/C9CS00271E ↗
5. Lu · Nat. Commun. · 2017 · 8
6. Kuai · Sci. Adv. · 2018 · 410.1126/sciadv.aao1736 ↗
7. Wang · Nano Lett. · 2019 · 19 · 526610.1021/acs.nanolett.9b01717 ↗
8. Chao · Nat. Biomed. Eng. · 2018 · 2 · 611-+10.1038/s41551-018-0262-6 ↗
9. Ni · Nat. Commun. · 2018 · 9
10. Chen · Nat. Commun. · 2016 · 7
11. Song · ACS Nano · 2018 · 12 · 197810.1021/acsnano.7b09112 ↗
12. Yu · ACS Nano · 2017 · 11 · 1014710.1021/acsnano.7b04736 ↗
13. Wang · Nano Lett. · 2016 · 16 · 550310.1021/acs.nanolett.6b01994 ↗
14. He · Nat. Commun. · 2016 · 7
15. Duan · J. Am. Chem. Soc. · 2016 · 138 · 1668610.1021/jacs.6b09538 ↗
16. Lu · J. Am. Chem. Soc. · 2016 · 138 · 1250210.1021/jacs.6b06663 ↗
17. Ji · Angew. Chem. Int. Ed. · 2018 · 57 · 1138410.1002/anie.201807602 ↗
18. Cai · Angew. Chem. Int. Ed. · 2020 · 59 · 1401410.1002/anie.202001107 ↗
19. Liu · Adv. Mater. · 2018 · 30
20. Cheng · Nat. Commun. · 2015 · 6
21. Yang · Nat. Commun. · 2017 · 8
22. Fan · Adv. Mater. · 2015 · 27 · 415510.1002/adma.201405141 ↗
23. Wang · Sci. Transl. Med. · 2018 · 10
24. Pollard · Nat. Rev. Cancer · 2004 · 4 · 7110.1038/nrc1256 ↗
25. Biswas · Nat. Immunol. · 2010 · 11 · 88910.1038/ni.1937 ↗
26. Noy · Immunity · 2014 · 41 · 4910.1016/j.immuni.2014.06.010 ↗
27. Nishikawa · Curr. Opin. Immunol. · 2014 · 27 · 110.1016/j.coi.2013.12.005 ↗
28. Zou · Nat. Rev. Immunol. · 2006 · 6 · 29510.1038/nri1806 ↗
29. Togashi · Immunity · 2017 · 41 · 3
30. Buchbinder · Nat. Rev. Clin. Oncol. · 2016 · 13 · 7710.1038/nrclinonc.2015.237 ↗
31. Errico · Nat. Rev. Clin. Oncol. · 2015 · 12 · 6310.1038/nrclinonc.2014.221 ↗
32. Xu · ACS Nano · 2017 · 11 · 446310.1021/acsnano.7b00715 ↗
33. Zanganeh · Nat. Nanotechnol. · 2016 · 11 · 98610.1038/nnano.2016.168 ↗
34. An · ACS Appl. Mater. Inter. · 2013 · 5 · 1324810.1021/am4042367 ↗
35. An · Small · 2015 · 11 · 567510.1002/smll.201501491 ↗
36. Bhattacharjee · Biochimie · 2011 · 93 · 129710.1016/j.biochi.2011.05.038 ↗
37. Mandai · Clin. Cancer Res. · 2016 · 22 · 232910.1158/1078-0432.CCR-16-0224 ↗
38. Wandel · Cell Host Microbe · 2017 · 22 · 50710.1016/j.chom.2017.09.007 ↗
39. Man · J. Leukoc. Biol. Suppl. · 2017 · 101 · 14310.1189/jlb.4MR0516-223R ↗
40. Kim · Science · 2011 · 332 · 71710.1126/science.1201711 ↗
41. Mustafa · Acta Neuropathol. · 2018 · 135 · 58110.1007/s00401-018-1806-2 ↗
42. Zhang · Cell Death Dis. · 2017 · 8 · e315110.1038/cddis.2017.559 ↗
43. Stebbing · Oncogene · 2015 · 34 · 210310.1038/onc.2014.129 ↗
44. Thomsen · Cell Death Differ. · 2015 · 22 · 57410.1038/cdd.2014.213 ↗
45. Lee · Chem. Soc. Rev. · 2012 · 41 · 257510.1039/C1CS15248C ↗
46. Rastinehad · Proc. Natl. Acad. Sci. U. S. A. · 2019 · 116 · 1859010.1073/pnas.1906929116 ↗